Goodwin Procter advised Grey Wolf Therapeutics on the deal, while DLA Piper advised Pfizer Ventures and Earlybird Venture Capital. Grey Wolf Therapeutics announced its $49 million Series B...
Grey Wolf Therapeutics’ $49 Million Series B Funding Round
Anjarium Biosciences’ CHF 55.5 Million Series A Financing Round
VISCHER advised Anjarium Biosciences on the deal. Baker McKenzie advises a consortium of life science funds, including Abingworth and Gimv, alongside Omega Funds, Pfizer Ventures and...